169 related articles for article (PubMed ID: 18990504)
21. Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting.
Puente J; Grande E; Medina A; Maroto P; Lainez N; Arranz JA
Ther Adv Med Oncol; 2017 May; 9(5):307-318. PubMed ID: 28529548
[TBL] [Abstract][Full Text] [Related]
22. The role of chemotherapy and new targeted agents in the management of primary prostate cancer.
Kumar SS; Pacey S
J Clin Urol; 2016 Dec; 9(2 Suppl):30-37. PubMed ID: 28344814
[TBL] [Abstract][Full Text] [Related]
23. Analysis of Argonaute Complex Bound mRNAs in DU145 Prostate Carcinoma Cells Reveals New miRNA Target Genes.
Szczyrba J; Jung V; Beitzinger M; Nolte E; Wach S; Hart M; Sapich S; Wiesehöfer M; Taubert H; Wennemuth G; Eichner N; Stempfl T; Wullich B; Meister G; Grässer FA
Prostate Cancer; 2017; 2017():4893921. PubMed ID: 28163933
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer: No evidence for adjuvant chemotherapy in high-risk disease.
Albers P
Nat Rev Urol; 2015 Nov; 12(11):602-3. PubMed ID: 26334083
[No Abstract] [Full Text] [Related]
25. The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.
Diamond E; Garcias Mdel C; Karir B; Tagawa ST
Curr Treat Options Oncol; 2015 Feb; 16(2):9. PubMed ID: 25762124
[TBL] [Abstract][Full Text] [Related]
26. Tolerance of Phellodendron amurense bark extract (Nexrutine®) in patients with human prostate cancer.
Swanson GP; Jones WE; Ha CS; Jenkins CA; Kumar AP; Basler J
Phytother Res; 2015 Jan; 29(1):40-2. PubMed ID: 25205619
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy.
Kamrava M; Kesarwala AH; Madan RA; Lita E; Kaushal A; Tsang KY; Poole DJ; Steinberg SM; Ferrara T; Dahut W; Schlom J; Gulley JL
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):289-95. PubMed ID: 22391584
[TBL] [Abstract][Full Text] [Related]
29. Management of high-risk localized prostate cancer.
Marciscano AE; Hardee ME; Sanfilippo N
Adv Urol; 2012; 2012():641689. PubMed ID: 22110494
[TBL] [Abstract][Full Text] [Related]
30. Treatment strategies for high-risk locally advanced prostate cancer.
Rosenthal SA; Sandler HM
Nat Rev Urol; 2010 Jan; 7(1):31-8. PubMed ID: 20062072
[TBL] [Abstract][Full Text] [Related]
31. Innovations in the systemic therapy of prostate cancer.
Shepard DR; Raghavan D
Nat Rev Clin Oncol; 2010 Jan; 7(1):13-21. PubMed ID: 19997075
[TBL] [Abstract][Full Text] [Related]
32. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
Rosenthal SA; Hunt D; Sartor AO; Pienta KJ; Gomella L; Grignon D; Rajan R; Kerlin KJ; Jones CU; Dobelbower M; Shipley WU; Zeitzer K; Hamstra DA; Donavanik V; Rotman M; Hartford AC; Michalski J; Seider M; Kim H; Kuban DA; Moughan J; Sandler H
Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):294-302. PubMed ID: 26209502
[TBL] [Abstract][Full Text] [Related]
33. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
34. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
Milecki P; Kwias Z; Martenka DJ
Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
[TBL] [Abstract][Full Text] [Related]
35. Current trials and new aspects in soft tissue sarcoma of adults.
Issels RD; Schlemmer M
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
[TBL] [Abstract][Full Text] [Related]
36. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
[TBL] [Abstract][Full Text] [Related]
37. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E;
Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
